CLINICAL TRIALS ENROLLED PATIENTS
DESPITE PRIOR SURGERY OR SCS USE^1,2

Patients enrolled were continued on background INCS throughout the duration of both trials

	TRIAL 1 (N=276) 24 WEEKS	TRIAL 2 (N=448) 52 WEEKS
Randomized	DUPIXENT + INCS 300 mg Q2W for 24 weeks (n=143) Placebo + INCS for 24 weeks (n=133)	DUPIXENT + INCS 300 mg Q2W for 52 weeks (n=150)^a DUPIXENT + INCS 300 mg Q2W for 24 weeks, followed by Q4W^b through Week 52 (n=145)^a Placebo + INCS for 52 weeks (n=153)
Study population	Adults (≥18 years) on background INCS^c with CRSwNP despite prior sino-nasal surgery or prior treatment with, or who were ineligible to receive or were intolerant to, systemic corticosteroids in the past 2 years Patients with chronic rhinosinusitis without nasal polyposis were not included in these trials Rescue with systemic corticosteroids or surgery was allowed at investigators’ discretion The total population of patients in Trials 1 and 2 was unrestricted by minimum baseline blood eosinophil count
Coprimary endpoints	Change from baseline at Week 24 in: Nasal congestion/obstruction (NC) score averaged over 28 days Bilateral endoscopic nasal polyps score (NPS)
Key secondary endpoints	Change from baseline at Week 24 in: Daily loss of smell score LMK-CT score SNOT-22 score UPSIT score	Change from baseline at Weeks 24 and 52 in: NC score (at Week 52) NPS (at Week 52) Daily loss of smell score LMK-CT score SNOT-22 score UPSIT score
Additional endpoints	Change from baseline at Week 24 in FEV₁ and ACQ-6 scores in patients with comorbid asthma
Prespecified pooled analysis	Change from baseline at Week 52 in proportion of patients requiring SCS or sino-nasal surgery

TRIAL 1
(N=276) 24 WEEKS

Randomized

DUPIXENT + INCS
300 mg Q2W for 24 weeks (n=143)
Placebo + INCS for 24 weeks (n=133)

Study population

Adults (≥18 years) on background INCS^a with CRSwNP despite prior sino-nasal surgery or prior treatment with, or who were ineligible to receive or were intolerant to, systemic corticosteroids in the past 2 years

Patients with chronic rhinosinusitis without nasal polyposis were not included in these trials

Rescue with systemic corticosteroids or surgery was allowed at investigators’ discretion

The total population of patients in Trials 1 and 2 was unrestricted by minimum baseline blood eosinophil count

Coprimary endpoints

Change from baseline at Week 24 in:

Nasal congestion/obstruction (NC) score averaged over 28 days
Bilateral endoscopic nasal polyps score (NPS)

Key secondary endpoints

Change from baseline at Week 24 in:

Daily loss of smell score
LMK-CT score
SNOT-22 score
UPSIT score

Additional endpoints

Change from baseline at Week 24 in FEV₁ and ACQ-6 scores in patients with comorbid asthma

Prespecified pooled analysis

Change from baseline at Week 52 in proportion of patients requiring SCS or sino-nasal surgery

TRIAL 2
(N=448) 52 WEEKS

Randomized

DUPIXENT + INCS
300 mg Q2W for 52 weeks (n=150)^b
DUPIXENT + INCS
300 mg Q2W for 24 weeks, followed by Q4W^c through Week 52 (n=145)^b
Placebo + INCS for 52 weeks (n=153)

Study population

Patients with chronic rhinosinusitis without nasal polyposis were not included in these trials

Rescue with systemic corticosteroids or surgery was allowed at investigators’ discretion

The total population of patients in Trials 1 and 2 was unrestricted by minimum baseline blood eosinophil count

Coprimary endpoints

Change from baseline at Week 24 in:

Nasal congestion/obstruction (NC) score averaged over 28 days
Bilateral endoscopic nasal polyps score (NPS)

Key secondary endpoints

Change from baseline at Weeks 24 and 52 in:

NC score (at Week 52)
NPS (at Week 52)
Daily loss of smell score
LMK-CT score
SNOT-22 score
UPSIT score

Additional endpoints

Change from baseline at Week 24 in FEV₁ and ACQ-6 scores in patients with comorbid asthma

Prespecified pooled analysis

Change from baseline at Week 52 in proportion of patients requiring SCS or sino-nasal surgery

^aIn Trial 2, data from baseline to Week 24 are pooled from DUPIXENT Q2W treatment arms (n=295).
^bThe recommended dose of DUPIXENT for adult patients with CRSwNP is 300 mg given subcutaneously every other week.
^cAll patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray.

^aAll patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray.
^bIn Trial 2, data from baseline to Week 24 are pooled from DUPIXENT Q2W treatment arms (n=295).
^cThe recommended dose of DUPIXENT for adult patients with CRSwNP is 300 mg given subcutaneously every other week.

ALL PRIMARY AND SECONDARY ENDPOINTS WERE MET WITH STATISTICAL SIGNIFICANCE^1,2

Patient demographics¹

TRIAL 1: 24 WEEKS (N=276)–Mean age: 50 years; male: 57%; mean CRSwNP duration: 11 years; patients with ≥1 prior surgery: 72%; patients with SCS use in previous 2 years: 65%; mean bilateral endoscopic NPS,^d range 0-8: 5.8; mean NC score,^d range 0-3: 2.4; mean LMK sinus CT total score,^d range 0-24: 19; mean loss of smell score^d (AM), range 0-3: 2.7; mean SNOT-22 total score,^d range 0-110: 49.4; mean blood eosinophil count: 440 cells/μL; mean total IgE: 212 IU/mL; atopic medical history, overall: 75%; asthma: 58%; NSAID-ERD: 30%.

TRIAL 2: 52 WEEKS (N=448)–Mean age: 52 years; male: 62%; mean CRSwNP duration: 11 years; patients with ≥1 prior surgery: 58%; patients with SCS use in previous 2 years: 80%; mean bilateral endoscopic NPS,^d range 0-8: 6.1; mean NC score,^d range 0-3: 2.4; mean LMK sinus CT total score,^d range 0-24: 18; mean loss of smell score^d (AM), range 0-3: 2.8; mean SNOT-22 total score,^d range 0-110: 51.9; mean blood eosinophil count: 430 cells/μL; mean total IgE: 240 IU/mL; atopic medical history, overall: 82%; asthma: 60%; NSAID-ERD: 27%.

~79% of patients enrolled in both trials had atopic diseases

In Trials 1 and 2, all subjects had evidence of sinus opacification on the LMK sinus CT scan, and 73% to 90% of subjects had opacification of all sinuses. Prior surgery patients had a mean number of 2.0 prior surgeries, and SCS use patients had 1.6 SCS courses in the previous 2 years.

^dHigher scores indicate greater disease severity.
AM, morning; ACQ-6, Asthma Control Questionnaire, 6-item version; CRSwNP, chronic rhinosinusitis with nasal polyposis; FEV₁, forced expiratory volume in 1 second; INCS, intranasal corticosteroids; LMK-CT, Lund-Mackay computed tomography; NSAID-ERD, nonsteroidal anti-inflammatory drug–exacerbated respiratory disease; Q2W, once every 2 weeks; Q4W, once every 4 weeks; SCS, systemic corticosteroid; SNOT-22, 22-item Sino-Nasal Outcome Test; UPSIT, University of Pennsylvania Smell Identification Test.

SEE THE Safety data

References:

DUPIXENT Prescribing Information.
Data on file, Sanofi US. Clinical overview (chronic rhinosinusitis with nasal polyposis). 2018.

Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis occurred more frequently in subjects with chronic rhinosinusitis with nasal polyposis who received DUPIXENT. There were no cases of keratitis reported in the CRSwNP development program. Among asthma subjects, the frequencies of conjunctivitis and keratitis were similar between DUPIXENT and placebo. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-Morbid Asthma: Advise patients with CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS:

Asthma: The most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.
Chronic rhinosinusitis with nasal polyposis: The most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information

Indications

Asthma: DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic rhinosinusitis with nasal polyposis (CRSwNP): DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.

CLINICAL TRIALS ENROLLED PATIENTS DESPITE PRIOR SURGERY OR SCS USE1,2

Patients enrolled were continued on background INCS throughout the duration of both trials

TRIAL 1 (N=276) 24 WEEKS

TRIAL 2(N=448) 52 WEEKS

Patient demographics1

Identify CRSwNP patients appropriate for DUPIXENT

Dosing & Administration

Contact a Rep

DUPIXENT MyWay®

Leaving to HCP site

You are leaving a Sanofi US website

Are you sure you want to leave?

You are about to leave sanofi site for U.S.

You are about to move to an Unbranded site

CLINICAL TRIALS ENROLLED PATIENTS
DESPITE PRIOR SURGERY OR SCS USE^1,2

TRIAL 1
(N=276) 24 WEEKS

TRIAL 2
(N=448) 52 WEEKS

Patient demographics¹

Identify CRSwNP
patients appropriate
for DUPIXENT

DUPIXENT MyWay^®